

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



File Copy

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, C12N 15/11, C12Q 1/68, C07K 16/18, G01N 33/68, A61K 38/17		A2	(11) International Publication Number: WO 00/00610 (43) International Publication Date: 6 January 2000 (06.01.00)																												
(21) International Application Number: PCT/US99/14484 (22) International Filing Date: 25 June 1999 (25.06.99) (30) Priority Data: <table border="0"><tr><td>60/090,762</td><td>26 June 1998 (26.06.98)</td><td>US</td></tr><tr><td>60/094,983</td><td>31 July 1998 (31.07.98)</td><td>US</td></tr><tr><td>60/102,686</td><td>1 October 1998 (01.10.98)</td><td>US</td></tr><tr><td>60/112,129</td><td>11 December 1998 (11.12.98)</td><td>US</td></tr></table> (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications <table border="0"><tr><td>US</td><td>60/090,762 (CIP)</td></tr><tr><td>Filed on</td><td>26 June 1998 (26.06.98)</td></tr><tr><td>US</td><td>60/094,983 (CIP)</td></tr><tr><td>Filed on</td><td>31 July 1998 (31.07.98)</td></tr><tr><td>US</td><td>60/102,686 (CIP)</td></tr><tr><td>Filed on</td><td>1 October 1998 (01.10.98)</td></tr><tr><td>US</td><td>60/112,129 (CIP)</td></tr><tr><td>Filed on</td><td>11 December 1998 (11.12.98)</td></tr></table> (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		60/090,762	26 June 1998 (26.06.98)	US	60/094,983	31 July 1998 (31.07.98)	US	60/102,686	1 October 1998 (01.10.98)	US	60/112,129	11 December 1998 (11.12.98)	US	US	60/090,762 (CIP)	Filed on	26 June 1998 (26.06.98)	US	60/094,983 (CIP)	Filed on	31 July 1998 (31.07.98)	US	60/102,686 (CIP)	Filed on	1 October 1998 (01.10.98)	US	60/112,129 (CIP)	Filed on	11 December 1998 (11.12.98)	(72) Inventors; and (75) Inventors/Applicants (for US only): LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AKERBLOM, Ingrid, E. [US/US]; 1234 Johnson Street, Redwood City, CA 94061 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
60/090,762	26 June 1998 (26.06.98)	US																													
60/094,983	31 July 1998 (31.07.98)	US																													
60/102,686	1 October 1998 (01.10.98)	US																													
60/112,129	11 December 1998 (11.12.98)	US																													
US	60/090,762 (CIP)																														
Filed on	26 June 1998 (26.06.98)																														
US	60/094,983 (CIP)																														
Filed on	31 July 1998 (31.07.98)																														
US	60/102,686 (CIP)																														
Filed on	1 October 1998 (01.10.98)																														
US	60/112,129 (CIP)																														
Filed on	11 December 1998 (11.12.98)																														
(54) Title: HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS																															
(57) Abstract <p>The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.</p>																															

	440		445		450
Glu Ser Ser Pro	Gly Ala Thr Gly Ser	Phe Thr Tyr Glu Ala Val			
	455		460		465
Glu Leu Val Pro	Ala Gly Ala Pro Thr	Gln Ala Ala Trp Leu Ala			
	470		475		480
Ala Leu Ser Asp	Arg Glu Thr Arg Leu	Gln Glu Val Arg Ser Ala			
	485		490		495
Phe Leu Ala Ala	Tyr Ser Ser Thr Val	Gly Leu Arg Ala Val Ala			
	500		505		510
Pro Ser Pro Ser	Gly Ala Ile Gly Gly	Leu Leu Glu Gln Phe Ala			
	515		520		525
Arg Gly Val Gly	Leu Arg Ser Ile Ser	Ser Asn Ala Leu			
	530		535		

<210> 93
 <211> 58
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 2831245

<400> 93
Met Glu Met Lys Gly Ser Arg Val Trp Leu Leu Leu Phe Met
1 5 10 15
Trp Lys Ala Arg Pro Thr Phe Phe Gln Ser Cys Val Val Pro Phe
20 25 30
Ile Leu Ser Pro Gln Asn Cys Val Gln Thr His Ser Leu Gly Pro
35 40 45
Gly Val Trp Leu Gly Val Phe Pro Ser Gly Ser Leu His
50 55

<210> 94
 <211> 119
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 3116250

<400> 94
Met Lys Val Leu Ile Ser Ser Leu Leu Leu Leu Pro Leu Met
1 5 10 15
Leu Met Ser Met Val Ser Ser Ser Leu Asn Pro Gly Val Ala Arg
20 25 30
Gly His Arg Asp Arg Gly Gln Ala Ser Arg Arg Trp Leu Gln Glu
35 40 45
Gly Gly Gln Glu Cys Glu Cys Lys Asp Trp Phe Leu Arg Ala Pro
50 55 60

```

Arg Arg Lys Phe Met Thr Val Ser Gly Leu Pro Lys Lys Gln Cys
      65              70              75
Pro Cys Asp His Phe Lys Gly Asn Val Lys Lys Thr Arg His Gln
      80              85              90
Arg His His Arg Lys Pro Asn Lys His Ser Arg Ala Cys Gln Gln
      95             100             105
Phe Leu Lys Gln Cys Gln Leu Arg Ser Phe Ala Leu Pro Leu
      110             115

```

<210> 95
 <211> 128
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 3129630

```

<400> 95
Met Ala Tyr Ser Thr Val Gln Arg Val Ala Leu Ala Ser Gly Leu
 1          5              10              15
Val Leu Ala Leu Ser Leu Leu Leu Pro Lys Ala Phe Leu Ser Arg
      20              25              30
Gly Lys Arg Gln Glu Pro Pro Pro Thr Pro Glu Gly Lys Leu Gly
      35              40              45
Arg Phe Pro Pro Met Met His His His Gln Ala Pro Ser Asp Gly
      50              55              60
Gln Thr Pro Gly Ala Arg Phe Gln Arg Ser His Leu Ala Glu Ala
      65              70              75
Phe Ala Lys Ala Lys Gly Ser Gly Gly Gly Ala Gly Gly Gly Gly
      80              85              90
Ser Gly Arg Gly Leu Met Gly Gln Ile Ile Pro Ile Tyr Gly Phe
      95             100             105
Gly Ile Phe Leu Tyr Ile Leu Tyr Ile Leu Phe Lys Val Ser Arg
      110             115             120
Ile Ile Leu Ile Ile Leu His Gln
      125

```

<210> 96
 <211> 124
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone No: 007632

```

<400> 96
Met Tyr Lys Leu Ala Ser Cys Cys Leu Leu Phe Ile Gly Phe Leu
 1          5              10              15
Asn Pro Leu Leu Ser Leu Pro Leu Leu Asp Ser Arg Glu Ile Ser

```

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134 (SEQ ID NO:1-134), and fragments thereof.
2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.

3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
- (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ

ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268 (SEQ ID NO:135-268), and fragments thereof.

- 15 10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.
11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide
- 20 of claim 3.
13. A host cell comprising the expression vector of claim 12.
14. A method for producing a polypeptide, the method comprising the steps of:
 - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
 - 25 b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.
16. A purified antibody which specifically binds to the polypeptide of claim 1.
17. A purified agonist of the polypeptide of claim 1.
- 30 18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased expression or activity of HSPP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

20. A method for treating or preventing a disorder associated with increased
5 expression or activity of HSPP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.